company background image
4RY logo

Akeso DB:4RY Stock Report

Last Price

€7.25

Market Cap

€6.6b

7D

-16.2%

1Y

53.6%

Updated

13 Oct, 2024

Data

Company Financials +

4RY Stock Overview

A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.

4RY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Akeso, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Akeso
Historical stock prices
Current Share PriceHK$7.25
52 Week HighHK$8.65
52 Week LowHK$3.60
Beta0.51
11 Month Change3.57%
3 Month Change61.11%
1 Year Change53.60%
33 Year Change51.67%
5 Year Changen/a
Change since IPO121.27%

Recent News & Updates

Recent updates

Shareholder Returns

4RYDE BiotechsDE Market
7D-16.2%-0.3%0.8%
1Y53.6%-12.1%14.0%

Return vs Industry: 4RY exceeded the German Biotechs industry which returned -12.1% over the past year.

Return vs Market: 4RY exceeded the German Market which returned 14% over the past year.

Price Volatility

Is 4RY's price volatile compared to industry and market?
4RY volatility
4RY Average Weekly Movement11.0%
Biotechs Industry Average Movement6.4%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 4RY's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4RY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20122,815Michelle Xiawww.akesobio.com

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.

Akeso, Inc. Fundamentals Summary

How do Akeso's earnings and revenue compare to its market cap?
4RY fundamental statistics
Market cap€6.57b
Earnings (TTM)-€95.16m
Revenue (TTM)€242.54m

27.1x

P/S Ratio

-69.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4RY income statement (TTM)
RevenueCN¥1.87b
Cost of RevenueCN¥146.05m
Gross ProfitCN¥1.73b
Other ExpensesCN¥2.46b
Earnings-CN¥735.33m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin92.21%
Net Profit Margin-39.24%
Debt/Equity Ratio64.2%

How did 4RY perform over the long term?

See historical performance and comparison